Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > GUDATE

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Apr 23, 2021 9:45am

110 Views

Post# 33054357

RE:GUDATE

Doccole wrote: Knight just bought a drug for Alzheimer's. Dano has been talking about Alzheimer's. We have a connection with GUD. How could this synergies play out?

That's a good question Doccole.
Not sure.

I would assume GUD wants to get their hands on ATE's future products in Latin America but not sure if they can agree on a price. I'm sure GUD's first interest is in bumping up revenue and enjoy the synergies of a Canada/LATAM combo.

I'm thinking ATE could easily use a generic to build their future drug - don't really need this one specifically. Time will tell if there's any connection but not necessarily.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload